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Abstract
Patients with the chronic bronchitis form of chronic obstructive
pulmonary disease and cystic fibrosis share similar clinical
features, including mucus obstruction of airways and the
development of chronic/recurrent airways infections that
oftenmanifest as disease exacerbations. There is growing evidence
that these diseases may have parallels in disease pathogenesis
as well, including cystic fibrosis transmembrane conductance
regulator dysfunction, mucus dehydration, and defective
mucociliary clearance. As progress is made in the development
of therapies that target the basic defects that lead to cystic fibrosis
lung disease, it is possible that similar approaches could also
benefit patients with chronic bronchitis. A deeper
understanding of how tobacco smoke and other triggers of
chronic bronchitis actually lead to disease, and exploration of
the concept that therapies that restore cystic fibrosis
transmembrane conductance regulator function, mucus
hydration, and/or mucociliary clearance may benefit patients
with chronic bronchitis, hold the prospect of significant
progress in treating this prevalent disease.
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Cystic fibrosis (CF) is an inherited disease
with clearly defined ion transport
abnormalities that lead to defective lung
host defenses (1). A growing understanding
of CF pathogenesis has guided the
development of therapeutics that
specifically target these basic defects and are
having a significant impact on the outcome
of this deadly disease. In recent years,
parallels between CF and cigarette smoke–
induced chronic bronchitis (CB) have been
identified (2–4), opening up the possibility
that specific treatment approaches used in
CF could have similar beneficial effects in
this much larger patient population (5).
Given that the treatment of chronic
obstructive pulmonary disease (COPD) has
been constrained largely to a narrow range of
therapeutic classes, namely bronchodilators
and antiinflammatory agents, the
identification of new therapeutic targets is
exciting and brings the hope that novel
treatment approaches could eventually have
an impact on patient outcomes.
In this article, we review shared themes
in CF and CB pathogenesis and outline
therapeutic approaches that address
abnormalities in airway surface liquid (ASL)
hydration and mucociliary clearance (MCC).
The Relationship between
Airway Surface Liquid
Hydration and
Mucus Transport
Patients with CF gradually develop
bronchiectatic lung disease, manifesting as
productive cough with markedly thickened
secretions and episodes of clinical
deterioration known as pulmonary
exacerbations. The evolution of CF lung
disease is typically a slowly progressive
process that begins early in life, although the
lung at birth is essentially normal. Our best
understanding of how CF lung disease
begins and progresses is based on well-
described ion transport defects. Specifically,
patients with CF lack cAMP-mediated anion
transport because of the absence of a
functional cystic fibrosis transmembrane
conductance regulator (CFTR) channel. The
relative importance of chloride vs,
bicarbonate transport continues to be
debated and may be tissue specific (e.g.,
intestine vs. lung vs. sweat gland) (6, 7). In
addition, epithelial sodium channel (ENaC)
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activity becomes dysregulated because of
the loss of CFTR’s inhibitory influence over
this channel (8, 9). Although abnormalities
in ion transport have been shown to cause
defects in bacterial killing using in vitro and
animal model systems (10), it is clear that
these specific ion transport defects also lead
to mucus dehydration and reduced
clearance (10, 11). Indeed, in vitro studies
have demonstrated that well-differentiated
airway epithelial cultures progressively lose
the ability to transport mucus as it becomes
progressively dehydrated, thus providing a
key mechanistic link between mucus
dehydration and defective mucus clearance
in patients (12). Ultimately, adherent
mucus plaques and mucus plugs provide a
nidus for the development of chronic
infection and inflammation, which, in turn,
drives airways destruction.
In vitro and animal model data
supporting the mucus dehydration
hypothesis are strong, and in vivo human
data linking mucus dehydration to defective
mucus clearance are growing. Sputum
samples collected from adults with CF are
markedly dehydrated, as demonstrated by
an elevation in the percent solids content.
Although airway secretions from healthy
subjects, collected via bronchoscopy or
sputum induction, typically contain z1.5%
solids content (or .98% water), the
sputum from a typical adult patient with
CF will containz6% solids. Mucus samples
removed from CF airways at the time of
lung transplant are typically even more
dehydrated (z12% solids) (13). Direct
sampling of mucus overlying the central
airways of young patients with CF (,4 yr of
age) using bronchoscopic techniques reveals
that their secretions are also abnormally
dehydrated (i.e., they have an elevated percent
solids content) but to a degree that is
intermediate between healthy volunteers and
adult subjects with CF (our unpublished data).
Together, these data suggest that ASL/mucus
dehydration is a process that progresses
through the lifespan of these patients.
Potential Mechanisms of
Airway Surface Liquid
Dehydration in Chronic
Bronchitis
Several laboratories have reported that
cigarette smoke, in both the acute and
chronic settings, may induce CFTR
dysfunction (2–4, 14, 15). Both in vitro and
in vivo studies have shown that CFTR-
mediated chloride transport is reduced by
cigarette smoke, and that these defects
may persist in former smokers with
COPD. In fact, evidence of systemic
CFTR dysfunction, including abnormal
sweat chloride values, has also been
demonstrated in active and former
smokers with COPD (14, 15). Given the
clinical and pathological parallels between
CF and CB, including mucus retention,
infection, and neutrophil-dominated
airways inflammation, it has been
hypothesized that acquired CFTR
dysfunction in COPD may play an
important role in disease pathogenesis.
Specifically, reduced CFTR function could
lead to ASL dehydration through the
mechanisms already described, and this
may result in defective mucus clearance.
To test this hypothesis, patients with
symptoms of CB and airways obstruction
(mean FEV1 61.6% of predicted)
underwent induced sputum and
bronchoscopic procedures to collect lower
airway secretions so that their solids
content, an index of hydration, could be
measured. Furthermore, MCC scans were
performed using gamma scintigraphy to
characterize the extent and pattern of
mucus clearance defects. Interestingly, a
moderate degree of mucus dehydration
was observed when comparing with
nonsmoking control subjects and
asymptomatic smokers without airways
obstruction, both in induced sputum (3%
vs. 1.7–1.9% solids in control subjects) and
in filter paper samples obtained via
bronchoscopy(4% vs. 1.5–2% solids in
control subjects). Furthermore, patients
with CB had reduced MCC rates when
compared with either smoking or
nonsmoking control subjects without
symptoms or airways obstruction. In fact,
the degree of mucus dehydration, as
assessed by filter paper sampling of the
lower airways, in fact correlated inversely
with the observed rate of MCC and lung
function in the same patient (12).
Although these data do not provide
definitive proof of causality, they clearly
demonstrate a connection among
progressive dehydration of the airways,
defective mucus transport, and disease
severity. Closer examination of MCC data
in patients with CB reveals a clear slowing
in the central airways, cilia-driven
clearance, but generally preserved cough-
driven clearance. In contrast, the MCC
defect described in patients with CF is most
apparent in the peripheral lung region, and
extremely poor cough clearance is also
characteristic (16, 17). How differences in
MCC patterns reflect the relevance of shared
and dissimilar disease mechanisms in CF
and CB is not yet clear but is worthy of
further investigation.
Translating Hydrator
Therapies from Cystic Fibrosis
to Chronic Bronchitis
Hypertonic Saline
The strong weight of evidence linking
mucus dehydration to the pathogenesis of
CF lung disease has been a major driver for
the development of new therapies that
target this problem. Perhaps the simplest
hydrator therapy to emerge is inhaled
hypertonic saline (HS). Clinically, twice-
daily HS was shown to dramatically reduce
pulmonary exacerbations over the course
of a 1-year clinical trial in patients with
CF while providing more modest
improvements in lung function (18). As a
result, HS is now used as a long-term
therapy in more than 60% of patients with
CF in the United States (19).
Studies that delve into the mechanisms
that underlie the benefits of HS in CF are
likely to shed light onto potential benefits
in CB as well. The inhalation of a
hyperosmotic solution, such as 7% sodium
chloride, drives the movement of water
down its concentration gradient across the
water-permeable airway epithelium into
the luminal compartment. This added
volume of water is expected to reduce the
concentration of mucus solids and thereby
improve the transportability of airway
secretions. HS may have other effects that
also improve mucus clearance, including
the disruption of ionic bonds and improved
rheologic properties (20). Several studies
have shown that the acute inhalation of
a hyperosmotic aerosol, such as HS or
mannitol, does indeed accelerate MCC in
multiple disease states (21–25). This effect
was predicted not to be durable, however,
particularly in CF, in which sodium
hyperabsorption may dominate basal ion
transport processes. In healthy subjects, it
has indeed been shown that HS has a short
pharmacodynamic effect on MCC (26).
Surprisingly, however, when the
pharmacodynamic effect of HS was
assessed in subjects with CF after 2 weeks
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of regular usage, a sustained improvement
in MCC (.8 h) was observed (16).
Subsequent studies suggested that even a
single dose of HS may have a prolonged
impact on MCC in adult patients with CF
(26), in marked contrast to that which was
observed in healthy subjects (27). The
working hypothesis explaining this
paradox is that the large burden of
dehydrated secretions in the CF airway can
serve as a reservoir for water driven into
the luminal compartment by HS, akin to a
dehydrated sponge. The creation of this
volume depot in the critically important
mucus layer may prevent it from being
rapidly reabsorbed across the epithelial
surface. If correct, this hypothesis also
suggests that the duration of effect, and
perhaps the efficacy, of HS may relate to
the severity of a patient’s lung disease and
mucus burden, with greater effects being
expected in patients with more advanced
disease.
When considering patients with CB,
the critical question that these data raise
is whether HS, by reversing mucus
dehydration, may effectively stimulate
mucus transport, reduce mucus
obstruction, and prevent disease
exacerbations in this population as well.
Not surprisingly, HS has been shown to
acutely stimulate MCC in patients with
the CB phenotype of COPD (12, 28).
Importantly, the delivery of 7% sodium
chloride via jet nebulizer also appears to
be well tolerated. The key unanswered
question, however, is whether long-term
use of HS will improve clinical outcomes.
Extrapolating from the CF experience,
perhaps the most likely benefit may be
a reduction in pulmonary exacerbations
in patients at high risk of these events.
Obviously, demonstration of this type of
benefit will require a large study over a
relatively long time period. Shorter-term
and mechanistic outcome measures that
may be of value include routine measures
of lung function, patient-reported
outcomes, and the assessment of the
sustained effect that repeated HS
treatments have on MCC. A small, short-
term study of this nature is currently
underway (www.clinicaltrials.gov identifier
[NCT 01792271]).
Other Hydrators
The development of other hydrator
therapies for CF has also been pursued
aggressively. Dry powder mannitol, sharing
an essentially identical mechanism of
action with HS, has already been approved
in Australia, the European Union, and the
United Kingdom. Therapies that block or
otherwise inhibit the activity of ENaC
are also in active development. ENaC
inhibitors reduce the reabsorption of fluid
from the ASL compartment and could
therefore serve as an adjunct to therapies
that increase fluid secretion into the airway.
Although inhaled amiloride, the
prototypical ENaC inhibitor, failed to show
significant clinical benefit in CF studies
(29, 30), newer agents with much greater
potency, longer duration of action, and
improved safety profiles have emerged
subsequently and have entered into
clinical trials. Finally, small molecule
modulators of the defective CFTR protein
itself have moved rapidly through clinical
development and are now available to
approximately 50% of patients with CF
(31–35). Although CFTR may have
pleotropic effects in the lung, CFTR
modulators may certainly be viewed as
“hydrators” because they have clearly been
shown to improve ASL volume in vitro.
Ivacaftor, a highly effective CFTR
modulator that is approved for patients
with CF carrying at least one gating
mutation, was shown to dramatically
increase MCC in patients with the G551D
mutation, highlighting the relationship
among ion transport, ASL hydration, and
MCC (36).
Given the possibility that HS may
prove to be too short acting or otherwise
ineffective in the CB population,
development of an appropriately designed
alternative agent that is potent and long
acting is an attractive therapeutic option
(Figure 1). Although sodium transport
may not be up-regulated in patients with
CB (unlike in those with CF), the use of an
ENaC blocker to inhibit this rate-limiting
step of fluid reabsorption could still prove
to be beneficial if mucus dehydration and
defective MCC are important parts of CB
disease pathogenesis. Agents that reduce
ENaC activity via indirect mechanisms,
such as the inhibition of surface proteases
that are involved in channel activation,
may also have potential usefulness. An
approach that combines an ENaC blocker
with a second agent that stimulates fluid
secretion, such as a hyperosmotic agent,
may also be very attractive and worthy
of investigation. Finally, stimulation of
chloride secretion via non-CFTR pathways
could be explored, including the use of
P2Y2 agonists that stimulate calcium-
activated chloride channels (37).
The evidence that CFTR dysfunction is
present in patients with COPD raises the
possibility that CFTR modulators could
also provide therapeutic benefit. Obviously,
these patients are expected to have a
normal CFTR gene sequence, and the
observed reduction in CFTR activity likely
results from a reduced number of channels
of the cell surface (2, 38). Ivacaftor is a
CFTR modulator that increases channel
gating and open probability of not only
mutant channels with gating abnormalities
(i.e., gating mutations, R117H, and
temperature- or chemically corrected
delF508), but also wild-type channels. It is
conceivable, and there is supporting in
vitro evidence, that treatment of a patient
with CB with reduced CFTR function
Protease inhibitors
(–)
(+) (+)(–)
Channel-activating
Protease
ENaC
Na+ Cl–
CaCC CFTR
ENaC Blocker
P2Y2 agonist
P2Y2
Ivacaftor
(–)
(+)
(+)
Figure 1. Hydration of airway surfaces is controlled by multiple ion channels. These channels and the
regulatory elements that govern their activity provide multiple potential therapeutic targets that
could be used to restore mucus hydration and clearance in patients with chronic bronchitis.
CaCC = calcium activated chloride channel; CFTR = cystic fibrosis transmembrane conductance
regulator; ENaC = epithelial sodium channel.
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using an effective CFTR modulator could
increase the activity of residual channels,
stimulate anion secretion, improve mucus
hydration, and accelerate MCC (5). It
seems likely, however, that the severity
of the baseline CFTR dysfunction may
influence whether this strategy is likely to
be effective. It is well known that patients
with mild CFTR mutations often have
normal lung function despite possessing
only 5 to 10% of wild-type channel
activity. Therefore, the question is whether
the reduction of CFTR activity in a patient
with CB to 20–40% of normal is sufficient
to be a primary driver of disease
pathogenesis, or whether such a patient
would benefit clinically from a CFTR
modulator that reverses this more
modest degree of channel dysfunction.
Furthermore, ivacaftor may reduce the
plasma membrane stability of CFTR, and
this could counteract any beneficial effect
on channel open probability (39, 40).
Therefore, although this hypothesis and
treatment avenue remain intriguing, future
studies that pursue this novel approach
will need to be studied carefully.
Unanswered Questions and a
Path Forward
Many questions surround the ASL
dehydration hypothesis and the potential
use of hydrator therapies for CB. Although
CFTR function appears to be reduced in
these patients, is the degree of this
function severe enough or relevant to
disease pathogenesis? Airway secretions
sampled from patients with CB are clearly
more dehydrated than in those from
healthy volunteers, but does this relate to
CFTR dysfunction and is the severity of
mucus dehydration sufficient to cause a
defect in mucociliary transport in vivo?
MCC is clearly abnormal in patients with
CB, but is the pattern of the clearance
defect similar to that of CF and reflective
of the same underlying disease
mechanisms, or perhaps more related to
the loss of ciliary function associated with
smoking (41)? The answers to all of these
important questions may inform us
regarding the likelihood of ASL
hydrators, as a class, to become a
clinically useful treatment approach.
Furthermore, these answers may direct us
to agents that have the greatest likelihood
of success and the identification of
patients that are most likely to respond. It
will take a significant effort, including the
conduct of clinical studies and treatment
trials, to answer many of these questions.
The use of appropriate outcome measures
that are sensitive to and predictive of
clinical benefits must also be developed to
allow the selection of agents worthy of the
investments needed to conduct large-
scale clinical trials. Ultimately, this work
and these investments are warranted,
given the magnitude of harm that this
disease inflicts on individuals and society
as a whole, and given the current dearth
of novel treatment approaches for COPD.
The possibility of being able to target
a novel element involved in disease
pathogenesis and thereby improve patient
outcomes is incredibly exciting and
brings hope for the future. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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